WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 407334

CAS#: 188817-13-2

Description: SC-560 is a potent, orally active and selective inhibitor of COX-1. Using human recombinant enzymes, the IC50 value for SC-560 with respect to COX-1 is 9 nM, while the corresponding IC50 value for COX-2 is 6.3 µM.1 Thus, SC-560 shows 700-fold selectivity for the COX-1 enzyme.

Price and Availability

Size Price Shipping out time Quantity
50mg USD 150 2 Weeks
100mg USD 250 2 Weeks
200mg USD 450 2 Weeks
500mg USD 950 2 Weeks
1g USD 1650 2 Weeks
5g USD 4950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-26. Prices are subject to change without notice.

SC-560, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 407334
Name: SC-560
CAS#: 188817-13-2
Chemical Formula: C17H12ClF3N2O
Exact Mass: 352.059
Molecular Weight: 352.7412
Elemental Analysis: C, 57.89; H, 3.43; Cl, 10.05; F, 16.16; N, 7.94; O, 4.54

Synonym: SC-560; SC 560; SC560.

IUPAC/Chemical Name: 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole


InChi Code: InChI=1S/C17H12ClF3N2O/c1-24-14-8-6-13(7-9-14)23-15(10-16(22-23)17(19,20)21)11-2-4-12(18)5-3-11/h2-10H,1H3

SMILES Code: FC(C1=NN(C2=CC=C(OC)C=C2)C(C3=CC=C(Cl)C=C3)=C1)(F)F

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Li W, Wan L, Zhai LY, Wang J. Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts. Int J Mol Sci. 2014 Oct 23;15(10):19265-80. doi: 10.3390/ijms151019265. PubMed PMID: 25342321; PubMed Central PMCID: PMC4227273.

2: Paskauskas S, Parseliunas A, Kerkadze V, Nobiling R, Schmidt J, Ryschich E. Blockade of leukocyte haptokinesis and haptotaxis by ketoprofen, diclofenac and SC-560. BMC Immunol. 2011 Nov 12;12:64. doi: 10.1186/1471-2172-12-64. PubMed PMID: 22078067; PubMed Central PMCID: PMC3247092.

3: Long S, Theiss KL, Mattei A, Loftin CD, Li T. Solid-state properties of the cyclooxygenase-1-selective inhibitor, SC-560. AAPS PharmSciTech. 2010 Jun;11(2):485-8. doi: 10.1208/s12249-010-9407-y. Epub 2010 Mar 20. PubMed PMID: 20306238; PubMed Central PMCID: PMC2902343.

4: Okamoto M, Sakai M, Goto Y, Salim MT, Baba C, Goto K, Watashi K, Shimotohno K, Baba M. Anti-bovine viral diarrhoea virus and hepatitis C virus activity of the cyclooxygenase inhibitor SC-560. Antivir Chem Chemother. 2009 Sep 25;20(1):47-54. doi: 10.3851/1372. PubMed PMID: 19794231.

5: Long S, Theiss KL, Li T, Loftin CD. Cyclo-oxygenase-1-selective inhibitor SC-560. Acta Crystallogr Sect E Struct Rep Online. 2009 Jan 23;65(Pt 2):o360. doi: 10.1107/S1600536809001779. PubMed PMID: 21581958; PubMed Central PMCID: PMC2968361.

6: Aldasoro M, Mauricio MD, Serna E, Cortina B, Segarra G, Medina P, Vila JM, Flor B, Lluch S. Effects of aspirin, nimesulide, and SC-560 on vasopressin-induced contraction of human gastroepiploic artery and saphenous vein. Crit Care Med. 2008 Jan;36(1):193-7. PubMed PMID: 18090373.

7: Lee E, Choi MK, Han IO, Lim SJ. Role of p21CIP1 as a determinant of SC-560 response in human HCT116 colon carcinoma cells. Exp Mol Med. 2006 Jun 30;38(3):325-31. PubMed PMID: 16819292.

8: Brenneis C, Maier TJ, Schmidt R, Hofacker A, Zulauf L, Jakobsson PJ, Scholich K, Geisslinger G. Inhibition of prostaglandin E2 synthesis by SC-560 is independent of cyclooxygenase 1 inhibition. FASEB J. 2006 Jul;20(9):1352-60. PubMed PMID: 16816110.

9: Lampiasi N, Foderà D, D'Alessandro N, Cusimano A, Azzolina A, Tripodo C, Florena AM, Minervini MI, Notarbartolo M, Montalto G, Cervello M. The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Mol Med. 2006 Feb;17(2):245-52. PubMed PMID: 16391822.

10: Teng XW, Davies NM. High-performance liquid chromatographic analysis of a selective cyclooxygenase-1 inhibitor SC-560 in rat serum: application to pharmacokinetic studies. J Pharm Biomed Anal. 2004 Sep 3;35(5):1143-7. PubMed PMID: 15336360.

11: Teng XW, Abu-Mellal AK, Davies NM. Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat. J Pharm Pharm Sci. 2003 May-Aug;6(2):205-10. PubMed PMID: 12935431.